Skip to main content
Journal cover image

Convection-enhanced delivery for high-grade glioma.

Publication ,  Journal Article
Kang, JH; Desjardins, A
Published in: Neurooncol Pract
February 2022

Glioblastoma (GBM) is the most common adult primary malignant brain tumor and is associated with a dire prognosis. Despite multi-modality therapies of surgery, radiation, and chemotherapy, its 5-year survival rate is 6.8%. The presence of the blood-brain barrier (BBB) is one factor that has made GBM difficult to treat. Convection-enhanced delivery (CED) is a modality that bypasses the BBB, which allows the intracranial delivery of therapies that would not otherwise cross the BBB and avoids systemic toxicities. This review will summarize prior and ongoing studies and highlights practical considerations related to clinical care to aid providers caring for a high-grade glioma patient being treated with CED. Although not the main scope of this paper, this review also touches upon relevant technical considerations of using CED, an area still under much development.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neurooncol Pract

DOI

ISSN

2054-2577

Publication Date

February 2022

Volume

9

Issue

1

Start / End Page

24 / 34

Location

England
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kang, J. H., & Desjardins, A. (2022). Convection-enhanced delivery for high-grade glioma. Neurooncol Pract, 9(1), 24–34. https://doi.org/10.1093/nop/npab065
Kang, Jennifer H., and Annick Desjardins. “Convection-enhanced delivery for high-grade glioma.Neurooncol Pract 9, no. 1 (February 2022): 24–34. https://doi.org/10.1093/nop/npab065.
Kang JH, Desjardins A. Convection-enhanced delivery for high-grade glioma. Neurooncol Pract. 2022 Feb;9(1):24–34.
Kang, Jennifer H., and Annick Desjardins. “Convection-enhanced delivery for high-grade glioma.Neurooncol Pract, vol. 9, no. 1, Feb. 2022, pp. 24–34. Pubmed, doi:10.1093/nop/npab065.
Kang JH, Desjardins A. Convection-enhanced delivery for high-grade glioma. Neurooncol Pract. 2022 Feb;9(1):24–34.
Journal cover image

Published In

Neurooncol Pract

DOI

ISSN

2054-2577

Publication Date

February 2022

Volume

9

Issue

1

Start / End Page

24 / 34

Location

England